

Regulated information
January 20, 2014 – 17:45 CET

Transparency Notification SRIW SA / SA SOFIPOLE

(Article 14 of the Law of 2 August 2007)

Mont-Saint-Guibert, Belgium - The biotechnology company, Cardio3 BioSciences SA (Cardio3 BioSciences), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces it has received a transparency declaration from SRIW SA/ Sofipôle SA in accordance with the Belgian Law of 2nd May 2007 concerning disclosure of major holdings in issuers whose shares are admitted to trading on a Belgian regulated market.

As of today, the Company's share capital amounts to EUR 22,138,007.93 and is represented by a total 6,332,792 shares (each share given one voting right).

Transparency notification from SRIW SA/Sofipole SA

Cardio3 BioSciences, received on January 16 2014, a transparency notification from SRIW SA/Sofipole, having passed, on January 15 2014, the 10% threshold.

- Reason for notification: transfer of shares
- Notification by a parent company or controlling person.
- Person (s) holding (s) notification

Name	Address
S.R.I.W SA	avenue Maurice Destenay 13, 4000 Liège
SOFIPOLE SA	avenue Maurice Destenay 13, 4000 Liège

Voting rights	Previous notification	Post the transaction			
	# voting rights	# voting rights		% voting rights	
Holders of voting rights		Attached to shares	Non related securities	Attached to shares	Non related securities
SRIW SA	290,526	290,526	-	4.59%	-
SOFIPOLE SA	370,646	300,738	-	4.75 %	-
TOTAL	661,172	591,264	-	9.34%	-

As a result of this transfer, Sofipôle has also passed the 5% threshold.

The Walloon Region owns 98.65% of SRIW SA, which owns 60% of shares in SOFIPOLE SA.

***** END *****

For more information contact:

Cardio3 BioSciences

Dr Christian Homsy, CEO

Anne Portzenheim, Communication Manager

www.c3bs.com

Tel : +32 10 39 41 00

aportzenheim@c3bs.com

Citigate Dewe Rogerson

David Dible/Chris Gardner/Malcolm Robertson

Tel : +44 (0) 207 638 9571

david.dible@citigatedr.co.uk

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle cells that behave identically to those lost to heart disease. This process is known as Cardiopoiesis.



Cardio3 BioSciences has also developed C-Cath^{®ez}, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on NYSE Euronext Brussels and NYSE Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities. As a result, of these factors investors and prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or review any forward-looking statement, whether as a result of new information, future events or otherwise